London, UK – Prokarium announced today the appointment of Peter McGowan as CFO. Peter will join the management team beginning in 2020 and will replace Peter Coleman, CEO, Cobra Biologics. Prokarium is a venture-backed biotechnology company developing microbial immunotherapies and vaccines.
Peter brings a wealth of international experience and expertise gained over 25 years in the healthcare industry, including having served most recently as SVP of Finance at Mundipharma. While at Mundipharma, he held various senior finance leadership roles and was integral in its establishment as a fully integrated global pharmaceutical business. Peter also worked at PPD, a contract research organisation. He honed his analytical skills in numerous positions in banking and finance both in Sydney and London. Peter is a fellow of the Association of Certified Chartered Accountants (ACCA) and has a degree in Business.